Anthropic, an artificial intelligence company, announced on Apr. 6 the acquisition of New York-based startup Coefficient Bio for approximately $400 million.
The move signals Anthropic's continued push into the healthcare and life sciences sectors as biopharma companies increasingly turn to AI technologies. The acquisition is expected to bolster Anthropic’s healthcare team, though details about the deal and its impact remain limited. According to The Information, which first reported the news citing an anonymous source familiar with the matter, specifics such as the exact transaction value and timeline for closing have not been disclosed. BioSpace has reached out to Anthropic for confirmation but has not received a response.
Coefficient Bio has operated mostly in stealth mode, with little public information available about its platform or technology. Its website provides no details and its LinkedIn page lists only a small number of employees. Attempts by BioSpace to contact Coefficient were unsuccessful.
The startup was co-founded by Nathan Frey and Samuel Stanton, both of whom previously worked on machine learning at Roche’s Genentech division. Stanton’s LinkedIn profile indicates he is now a full-time member of Anthropic’s technical staff. Aris Theologis serves as CEO of Coefficient and previously held leadership positions at Evozyne and Paragon Biosciences.
Anthropic's acquisition follows its October 2025 launch of Claude Life Sciences—a version of its machine learning model designed for professionals across biopharma industries including scientists, clinical trial coordinators, and regulatory managers. Major pharmaceutical companies such as Sanofi, Novo Nordisk, and AbbVie reportedly use Claude in their operations.
Industry observers note that large investments are being made in AI-driven drug development tools across biotech firms globally. Eli Lilly recently committed up to $2.75 billion towards expanding work with Insilico Medicine on AI-designed oral drugs targeting various conditions.
Tyrone Lam, chief business officer at GATC Health said: “The companies drawing the most serious investor attention right now, regardless if they’ve IPO’d, share a common characteristic: they’re using AI not just as a discovery accelerator, but as a risk communication tool.”
Experts suggest that advanced algorithms are also helping reinvigorate biopharma’s IPO market by enabling startups to better communicate risks while providing investors new ways to assess opportunities.
